Vogenx priced an $81.3 million IPO to fund continued development of mizagliflozin, a metabolic-disease candidate in development for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing’s syndrome. The offering gives the company fresh capital for multiple clinical fronts across metabolic indications. Vaderis Therapeutics closed an oversubscribed $152 million Series B to advance engasertib (VAD-044) in hereditary hemorrhagic telangiectasia through a global Phase III study (HEROIC). The funding was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, signaling strong investor appetite for later-stage rare-disease assets. In startup funding, Infinimmune secured $75 million in Series A financing to advance IL-22- and IL-13-targeting antibodies (IFX-101 and IFX-201) into clinic for atopic dermatitis in 2027. The round highlights ongoing venture demand for next-generation, longer-duration immune-modulating biologics.